Valeant Reports 1 Percent Growth for Bausch + Lomb Segment in Q3-2017

November 10, 2017: By Joan McKenna

Valeant PharmaceuticalsValeant reported Nov. 7 that its Bausch + Lomb/International segment grew 1 percent (2 percent cc) in Q3-2017 year over year and accounted for nearly 57 percent of Valeant’s total revenues.

Valeant’s revenues for the quarter totaled $2.2 billion, down 10 percent year over year. Its net income was $1.3 billion compared with a net loss of $1.22 billion for the same period in 2016.

BauschThe Bausch + Lomb segment’s revenues totaled $1.25 billion in the third quarter, up from $1.24 billion in Q3-2016.

Laval, Quebec-based Valeant also reported that it reduced total debt by about $6 billion since the end of the first quarter of 2016. The company’s current long-term debt is $27.43 billion.

“Valeant is a very different company today than it was a year ago,” CEO Joseph Papa said in a statement. “Under a new management team, we have strengthened our balance sheet and stabilized the company by simplifying our business and allocating resources more efficiently.”

Within the Bausch + Lomb/International segment, the Global Surgical segment posted $161 million in revenues in Q3-2017, a 4 percent increase over Q3-2016; the Global Vision Care segment reported $208 million, a 5 percent increase; Global Consumer Products posted revenues of $392 million, a decline of 2 percent; and Global Ophthalmology Rx reported revenues of $149 million, a decline of 8 percent.

Valeant updated its guidance for 2017, expecting full-year revenues in the range of $8.65 billion to $8.80 billion, down slightly from previous guidance of $8.70 billion to $8.90 billion.

Also, Valeant reported Nov. 6 that it gave back its Sprout subsidiary, maker of the female libido product Addyi, to the former owners for a 6 percent royalty on future sales of Addyi. Valeant acquired the unit for $1 billion in 2015.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Bausch + Lomb Inks Deal with Express Scripts Expanding Vyzulta Coverage

Melgen Seeks Bond, Appeals Conviction on Charges of Medicare Fraud

Avedro, FDA Agree on Design, Size of First Pivotal Phase III Trial for Epi-on Cross-linking

Iridex Reports 2017 Revenues of $41.6 Million

Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

Essex Bio-Technology Agrees to Invest $5 Million in MeiraGTx, Developer of Gene Therapies

Clearside Biomedical Announces $85 Million Public Offering

ViewPoint Raises $35 Million for Topical Treatment Candidate for Cataracts, Presbyopia

Okogen Raises $10 Million in Series A Round for Viral Conjunctivitis Candidate

SightLife Surgical Acquires KAMRA Corneal Inlay from AcuFocus

Major Leaguer Tommy Pham Plays Through Keratoconus

Glaukos Reports 2017 Net Sales of $159.3 Million

Imprimis Posts 2017 Revenues of $26.77 Million, a 34 Percent Increase

STAAR’s 2017 Net Sales Total $90.6 Million

US FDA Warns Consumers Not to Use Products from Cantrell Drug Company

IDx’ AI-Based Diagnostics System Meets Endpoints in Pivotal Trial for DR

Aerie Plans to Launch Rhopressa in Q2-2018, Expects 2018 Revenues of $20 Million to $30 Million

Valeant Reports 2017 Revenues of $8.72 Billion, a Decline of 10 Percent

Carl Zeiss Meditec Reports $359.7 Million in Revenues for First Quarter of FY2018, a 5.3 Percent Increase

Ophthotech Partners with UMass to Develop ‘Minigene’ Therapy for Retinal Disease

Coming soon

2018 IOL Report: A Global Market Analysis for 2017 to 2023